Completely devastating. Virtually no chance it hits the U.S. market this year. Trying to present this as a positive is beyond patronizing and a complete slap in the face. Everyone sees just how significant this is. How can you spend $9-10 Billion to purchase the compound and not have all of your regulatory affairs in order?
How will this now affect the primary care representatives that were hired? This company is way too top-heavy in management and in representatives to maintain this level over another year. There is going to have to be some sort of layoff within the next year. It doesn’t make sense to keep everyone here in CV when it is absolutely not necessary. Especially the managers, who serve no useful purpose at all. I think that’s become clearly evident even more so during this pandemic.
Novartis is paying the price NOW for what they did in the past with "Speaker Programs" the FDA doesn't forget. They delayed several new drugs at Merck after the Viox mess. The FDA could drag this out for 2 years .
